MX343918B - Construccion de adn inmunomodulador no codificante. - Google Patents

Construccion de adn inmunomodulador no codificante.

Info

Publication number
MX343918B
MX343918B MX2013007286A MX2013007286A MX343918B MX 343918 B MX343918 B MX 343918B MX 2013007286 A MX2013007286 A MX 2013007286A MX 2013007286 A MX2013007286 A MX 2013007286A MX 343918 B MX343918 B MX 343918B
Authority
MX
Mexico
Prior art keywords
dna construct
immunomodulatory dna
coding
coding immunomodulatory
immunomodulation
Prior art date
Application number
MX2013007286A
Other languages
English (en)
Other versions
MX2013007286A (es
Inventor
Schroff Matthias
Kleuss Christiane
Kapp Kerstin
Original Assignee
Mologen Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43598913&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX343918(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mologen Ag filed Critical Mologen Ag
Publication of MX2013007286A publication Critical patent/MX2013007286A/es
Publication of MX343918B publication Critical patent/MX343918B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una molécula de ácido nucleico y su uso para la modulación del sistema inmune. La presente invención proporciona una construcción de ADN para la inmunomodulación, comprendiendo al menos un nucleótido en conformación L.
MX2013007286A 2010-12-23 2011-12-23 Construccion de adn inmunomodulador no codificante. MX343918B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1021867.5A GB201021867D0 (en) 2010-12-23 2010-12-23 Non-coding immunomodulatory DNA construct
PCT/EP2011/074033 WO2012085291A1 (en) 2010-12-23 2011-12-23 Non-coding immunomodulatory dna construct

Publications (2)

Publication Number Publication Date
MX2013007286A MX2013007286A (es) 2013-12-06
MX343918B true MX343918B (es) 2016-11-29

Family

ID=43598913

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013007286A MX343918B (es) 2010-12-23 2011-12-23 Construccion de adn inmunomodulador no codificante.

Country Status (18)

Country Link
US (2) US20140010830A1 (es)
EP (1) EP2655623B2 (es)
JP (1) JP6027542B2 (es)
KR (2) KR101862271B1 (es)
CN (3) CN107384930B (es)
AU (1) AU2011347095B2 (es)
BR (1) BR112013015816B1 (es)
CA (1) CA2822377C (es)
DK (1) DK2655623T3 (es)
ES (1) ES2618783T5 (es)
GB (1) GB201021867D0 (es)
IL (1) IL227105A (es)
MX (1) MX343918B (es)
PL (1) PL2655623T3 (es)
RU (1) RU2583291C2 (es)
SG (1) SG191328A1 (es)
WO (1) WO2012085291A1 (es)
ZA (1) ZA201304999B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201021867D0 (en) 2010-12-23 2011-02-02 Mologen Ag Non-coding immunomodulatory DNA construct
AR095882A1 (es) 2013-04-22 2015-11-18 Hoffmann La Roche Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
GB2514591A (en) * 2013-05-30 2014-12-03 Mologen Ag Predictive biomarker for cancer therapy
AR097584A1 (es) 2013-09-12 2016-03-23 Hoffmann La Roche Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
CA2953216C (en) 2014-06-04 2020-12-22 Exicure, Inc. Multivalent delivery of immune modulators by liposomal spherical nucleic acids for prophylactic or therapeutic applications
CA2968531A1 (en) 2014-11-21 2016-05-26 Northwestern University The sequence-specific cellular uptake of spherical nucleic acid nanoparticle conjugates
US10347146B2 (en) * 2014-12-23 2019-07-09 International Business Machines Corporation Managing answer feasibility
LU92821B1 (en) * 2015-09-09 2017-03-20 Mologen Ag Combination comprising immunostimulatory oligonucleotides
GB2542425A (en) 2015-09-21 2017-03-22 Mologen Ag Means for the treatment of HIV
JP7138094B2 (ja) 2016-08-25 2022-09-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト マクロファージ活性化剤と組み合わせた抗ｃｓｆ－１ｒ抗体の間欠投与
JP7304287B2 (ja) 2016-12-22 2023-07-06 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｐｄ－ｌ１／ｐｄ１治療の不成功後の、抗ｐｄ－ｌ１抗体との組み合わせでの抗ｃｓｆ－１ｒ抗体を用いた腫瘍の治療
EP3610022A1 (en) 2017-04-14 2020-02-19 Tollnine, Inc. Immunomodulating polynucleotides, antibody conjugates thereof, and methods of their use
EP3392345A1 (en) 2017-04-22 2018-10-24 Mologen AG Biomarker for small cell lung cancer therapy
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
US20210155933A1 (en) 2017-08-31 2021-05-27 Gilead Sciences, Inc. Tlr-9 agonists for modulation of tumor microenvironment
US11806364B2 (en) 2017-09-28 2023-11-07 Industry-Academic Cooperation Foundation, Yonsei University Method for producing myeloid-derived suppressor cells, myeloid-derived suppressor cells produced thereby, and methods thereof
US10685050B2 (en) * 2018-04-23 2020-06-16 Adobe Inc. Generating a topic-based summary of textual content
KR20200138597A (ko) 2019-06-01 2020-12-10 서미주 클렌징 마스크팩

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
PT1027359E (pt) * 1996-10-16 2003-09-30 Ribapharm Inc L-nucleosideos monociclicos analogos e suas utilizacoes
US6251666B1 (en) † 1997-03-31 2001-06-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid catalysts comprising L-nucleotide analogs
DE19935756A1 (de) * 1999-07-27 2001-02-08 Mologen Forschungs Entwicklung Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
AU1656601A (en) * 1999-11-12 2001-06-12 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
EP1322656B1 (en) † 2000-09-26 2008-01-16 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
JP2005504020A (ja) * 2001-07-03 2005-02-10 アイシス・ファーマシューティカルス・インコーポレーテッド ヌクレアーゼ耐性キメラオリゴヌクレオチド
US7276489B2 (en) * 2002-10-24 2007-10-02 Idera Pharmaceuticals, Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
WO2003035836A2 (en) † 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
DE10211558A1 (de) * 2002-03-15 2003-10-09 Noxxon Pharma Ag Neue Formen RNAi
US8158768B2 (en) * 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
AU2004224762B2 (en) * 2003-03-26 2009-12-24 Kuros Us Llc Packaging of immunostimulatory oligonucleotides into virus-like particles: method of preparation and use
US8188254B2 (en) 2003-10-30 2012-05-29 Coley Pharmaceutical Gmbh C-class oligonucleotide analogs with enhanced immunostimulatory potency
WO2005076824A2 (en) 2004-02-03 2005-08-25 The Regents Of The University Of California Methods of treating irritable bowel syndrome
JP3976742B2 (ja) * 2004-02-27 2007-09-19 江守商事株式会社 インターフェロンアルファを誘導する免疫刺激オリゴヌクレオチド
KR20070028537A (ko) † 2004-06-15 2007-03-12 이데라 파마슈티칼즈, 인코포레이티드 면역자극 올리고누클레오티드 다량체
WO2007042554A2 (en) † 2005-10-12 2007-04-19 Cancer Research Technology Ltd. Methods and compositions for treating immune disorders
US7879992B2 (en) † 2005-01-31 2011-02-01 Isis Pharmaceuticals, Inc. Modification of MyD88 splicing using modified oligonucleotides
US8357665B2 (en) † 2005-10-12 2013-01-22 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (IRO) compounds to modulate toll-like receptor based immune response
US20100130593A1 (en) * 2006-06-13 2010-05-27 Bayhill Therapeutics, Inc. Methods and immune modulator nucleic acid compositions for preventing and treating disease
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
EP2152889B1 (en) * 2007-05-29 2017-03-15 Nature Technology Corporation Vectors and methods for genetic immunization
WO2009035554A2 (en) * 2007-09-07 2009-03-19 University Of Florida Research Foundation, Inc. Superior structure stability and selectivity of hairpin nucleic acid probes with an l-dna stem
KR20100068422A (ko) * 2007-10-09 2010-06-23 콜리 파마슈티칼 게엠베하 변경된 당 잔기를 함유하는 면역자극성 올리고뉴클레오티드 유사체
WO2010039137A1 (en) * 2008-10-02 2010-04-08 Idera Pharmaceuticals, Inc. Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
EP2246433A1 (de) * 2009-04-30 2010-11-03 Mologen AG Concatemere zur Immunmodulation
GB201021867D0 (en) † 2010-12-23 2011-02-02 Mologen Ag Non-coding immunomodulatory DNA construct

Also Published As

Publication number Publication date
CN103370417A (zh) 2013-10-23
GB201021867D0 (en) 2011-02-02
EP2655623B2 (en) 2023-08-30
KR102022031B1 (ko) 2019-09-17
ES2618783T5 (es) 2024-04-09
US20210340543A1 (en) 2021-11-04
CA2822377A1 (en) 2012-06-28
EP2655623A1 (en) 2013-10-30
ZA201304999B (en) 2014-02-26
CN107384930A (zh) 2017-11-24
PL2655623T3 (pl) 2017-06-30
RU2583291C2 (ru) 2016-05-10
KR20160113332A (ko) 2016-09-28
BR112013015816B1 (pt) 2021-03-02
WO2012085291A1 (en) 2012-06-28
BR112013015816A2 (pt) 2018-05-29
DK2655623T3 (en) 2017-04-03
KR101862271B1 (ko) 2018-05-30
IL227105A (en) 2017-09-28
AU2011347095A1 (en) 2013-07-25
JP2014504158A (ja) 2014-02-20
CN107384930B (zh) 2022-03-18
ES2618783T3 (es) 2017-06-22
AU2011347095B2 (en) 2016-04-28
KR20130126680A (ko) 2013-11-20
US20140010830A1 (en) 2014-01-09
CA2822377C (en) 2020-07-28
CN107299101A (zh) 2017-10-27
EP2655623B1 (en) 2017-02-22
SG191328A1 (en) 2013-07-31
MX2013007286A (es) 2013-12-06
RU2013132151A (ru) 2015-01-27
JP6027542B2 (ja) 2016-11-16

Similar Documents

Publication Publication Date Title
MX343918B (es) Construccion de adn inmunomodulador no codificante.
IL262667A (en) Nucleosides, nucleotides and modified nucleic acids, and their uses
HK1202310A1 (en) Single-stranded nucleic acid molecule having amino acid backbone
HK1212376A1 (en) Rna-guided human genome engineering rna
MX2013004338A (es) Secuencias de repeticiones palindromicas cortas separadas regularmente agrupadas-cas (crisp-cas).
KR101581655B9 (ko) 세포 내 관통능을 가지고 ｒｎａ 간섭을 유도하는 핵산 분자 및 그 용도
HK1203077A1 (en) Modified nucleoside, nucleotide, and nucleic acid compositions
EP2631291A4 (en) NUCLEIC ACID MOLECULES INDUCING RNA INTERFERENCE, AND USES THEREOF
MX344972B (es) Oligonucleotidos inmunoestimulantes.
EP2931319A4 (en) MODIFIED NUCLEIC ACID MOLECULES AND THEIR USES
IN2015DN01300A (es)
EP2861737A4 (en) GEN TARGETING IN PLANTS THROUGH DNA VIRUSES
EP2622064A4 (en) NUCLEOSIDES, NUCLEOTIDES AND MODIFIED NUCLEIC ACIDS AND USES THEREOF
IL222357A0 (en) Capping-prone rna polymerase enzymes and their applications
ZA201303390B (en) Consensus prostate antigens nucleic acid molecule encoding the same and vaccine and uses comprising the same
AU2011356210A8 (en) Novel fucosyltransferases and their applications
EP2576836A4 (en) COMPOSITIONS AND METHODS FOR NUCLEIC ACID SEQUENCING PURPOSES
EP2536739A4 (en) PRIMER AND METHOD FOR NUCLEIC ACIDIFICATION
EP2844772A4 (en) DNA SEQUENCING
GB2502195B (en) Purification of nucleic acids
PT2748320T (pt) Composições, métodos e kits para hibridação de ácidos nucleicos
EP2844767A4 (en) SYSTEMS AND METHODS FOR NUCLEIC ACID SEQUENCING
EP2814969A4 (en) DNA ASSIMILATION
EP2844775A4 (en) DNA SEQUENCING
EP2844774A4 (en) DNA SEQUENCING

Legal Events

Date Code Title Description
FG Grant or registration